Shunqing Wang

12PUBLICATIONS
38CO-AUTHORS
Molecular targetsHaematological tumoursHaematologySocial epidemiologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 05, 2026
Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.

|May 11, 2026
Somatic mutations in CSK disrupt immune regulation in a Chinese aplastic anemia cohort.

|Sep 15, 2025
Clinical outcomes of modified post-transplantation cyclophosphamide versus granulocyte colony-stimulating factor/anti-thymocyte globulin-based protocol in alternative donor transplantation for severe aplastic anaemia.

Liangliang Wu, Ming Zhou, Xiaowei Chen

|Aug 06, 2025
The endothelial activation and stress index as a risk factor for all-cause mortality in patients with anemia: a nationwide retrospective cross-sectional study.

Liangliang Wu, Gaiying Dong, Tingting Wu

|Feb 26, 2025
A first-in-class JAK/ROCK inhibitor, rovadicitinib, for glucocorticoid-refractory or -dependent chronic GVHD.

Yanmin M Zhao, Yi Luo, Jimin M Shi

|Jan 17, 2024
Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.

Peihong Wang, Yvyin Zhang, Rufang Xiang

Pageof 2

Frequent Collaborators

3 joint publications

Liangliang Wu

2 joint publications

Hai Yi

1 joint publications

Pei-Hua Lu

1 joint publications

Dai-Hong Liu